Skip to content
value.today

Boston Therapeutics, Inc.

🇺🇸 Manchester, New Hampshire, USAPharmaceuticalsFounded 2009
Total raised
$12 M
3 rounds on record
Latest round
$8 M
Jun 2021
First round on record
Jul 2013
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Boston Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2021$8 MNo. 3$2 to $10 million

Boston Therapeutics, Inc.: Raise no. 3, Jun 2021

Investors in this round

5 investors had bought by the notice of Jul 9, 2021: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Boston Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Convertible Note and Warrrants
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Ludvigson · Executive Officer, Director
  • Conroy Chi-Heng Cheng · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Ludvigson, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 9, 2021. Read the notice at the SEC.

debt, optionsSEC
Aug 2016$2 MNo. 2Under $2 million

Boston Therapeutics, Inc.: Raise no. 2, Aug 2016

Investors in this round

28 investors had bought by the notice of Sep 20, 2016: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Boston Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
$25,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible Promissory Notes and Warrants
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$160,000
Finders' fees
none
Paid to its own people
$100,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl W. Rausch · Executive Officer · CEO
  • Alan W. Hoberman · Director
  • Colin W. Neill · Director
  • Conroy Chi-Heng Cheng · Director
  • Rom W. Eliaz · Director · Chairman

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group, LLC (CRD 120708) · New York, New YorkSold in AL, AR, CA, FL, IA, IL, LA, MO, NJ, NM, NY, PA, TX, VA

Remarks in the notice

  • On fees: “Placement agent will receive a 10% commission and a warrant to purchase a number of shares equal to 10% of the aggregate number of shares sold.”
  • On the use of proceeds: “Working capital.”

Signed by Carl W. Rausch, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Sep 20, 2016. Read the notice at the SEC.

debt, optionsSEC
Jul 2013$2 MNo. 1$2 to $10 million

Boston Therapeutics, Inc.: Raise no. 1, Jul 2013

Investors in this round

1 investor had bought by the notice of Aug 7, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Boston Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $8 M offered; $6 M still to sell
Smallest investment taken
$1
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$60,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Platt, Ph. D. · Executive Officer, Director, Promoter
  • Kenneth Tassey, Jr. · Executive Officer, Director, Promoter
  • Carl H. Lueders · Director
  • Dale H. Conaway · Director
  • Henry H. Esber · Director
  • Rom H. Eliaz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. · New York, New YorkSold in all US states

Signed by Kenneth A. Tassey, Jr., President. Source: SEC Form D, newest notice filed Aug 7, 2013. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Boston Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2021).

    SEC Form D · Jul 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2021

That is all the official record says: Boston Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Boston Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
David LudvigsonPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2021)SEC Form 3
Garrett GruenerPersonnot statednot statedHeld Series C preferred stock, 10% owner, director (Form 3, 2022)SEC Form 3
Gregory T. SchiffmanPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2022)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Boston Therapeutics, Inc.
NameRoleNamed in
David LudvigsonExecutive officerJul 2021
Carl W. RauschCEOSep 2016
David Platt, Ph. D.Executive officerAug 2013
Kenneth Tassey, Jr.Executive officerAug 2013
Conroy Chi-Heng ChengDirectorJul 2021
David LudvigsonDirectorJul 2021
Alan W. HobermanDirectorSep 2016
Colin W. NeillDirectorSep 2016
Rom W. EliazChairmanSep 2016
Dale W. ConwayChairmanAug 2016
Henry W. EsberDirectorAug 2016
Carl H. LuedersDirectorAug 2013
Dale H. ConawayDirectorAug 2013
David Platt, Ph. D.DirectorAug 2013
Henry H. EsberDirectorAug 2013
Kenneth Tassey, Jr.DirectorAug 2013
Rom H. EliazDirectorAug 2013
David Platt, Ph. D.PromoterAug 2013
Kenneth Tassey, Jr.PromoterAug 2013